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INTRODUCTION
One in 70 women will be suffering from ovarian
cancer during her life, and borderline ovarian tu-
mors present in 15% of all epithelial ovarian tu-
mors. Borderline ovarian tumors are neoplasms
with changes in cell proliferation greater than that
seen in benign ovarian tumors of the same type,
but showed no destruction or invasion of the ovar-
ium stroma.1 Histologic type of borderline ovarian
tumors mostly found are serous or mucinous type
that show the feature of epithelial proliferation, ab-
normal nucleus, and mitotic activity in the inter-
mediate level, without any invasion into stroma.1,2
Compared with malignant epithelial ovarian tu-
mors which are invasive, borderline ovarian tu-
mors are found in young women and at an early
stage, with a good prognosis. The incidence rate of
borderline ovarian tumors was lower than invasive
ovarian cancer.2 Borderline ovarian tumors are
often called ’ovarian tumors of low malignant po-
tential’ because of the low histological differentia-
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Objective: To compare the expression of telomerase in benign ovar-
ian tumors and borderline ovarian tumors.
Methods: Thirteen samples of paraffin blocks of ovarian borderline
tumors and benign ovarian tumors were taken from patients who
underwent surgery from January 2006 to December 2011. In all
samples, we performed immunohistochemical staining to the paraf-
fin blocks. Semi quantitative determination of the expression of
telomerase is done by an Anatomic Pathology specialist and Gyne-
cologist, which already had the same perception about assessing the
standardization sample. We used Fisher’s test to analyze the data.
Results: There were significant relationship in the moderate expres-
sion of telomerase in the nucleus and cytoplasm between benign
and borderline ovarian tumors, with an odds ratio of moderate
telomerase expression in the cytoplasm and nucleus of 19.3 (95%
CI: 1.4 - 943) and 26 (95% CI : 2.3 - 1211). This means that the risk
of borderline ovarian tumors in the expression of moderate telom-
erase in the cytoplasm was 3.19 times compared to the negative ex-
pression, whereas in the nucleus it became 26-fold. There is no sig-
nificant relationship among menopause, age, and telomerase ex-
pression in the nucleus and cytoplasm.
Conclusion: There are significant differences in the expression of
moderate strength telomerase in nucleus and cytoplasm between
benign and borderline ovarian tumors.
[Indones J Obstet Gynecol 2013; 37-1: 32-40]
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Abstrak
Tujuan: Membandingkan ekspresi telomerase pada tumor ovarium ji-
nak dan tumor ovarium borderline.
Metode: Tiga belas sampel blok parafin tumor ovarium borderline
dan tumor jinak ovarium diambil dari pasien yang menjalani operasi
dari bulan Januari 2006 sampai bulan Desember 2011. Pada semua
sampel parafin blok dilakukan pewarnaan imunohistokimia. Penen-
tuan ekspresi telomerase secara semikuantitatif dikerjakan oleh dok-
ter spesialis Patologi Anatomi dan dokter spesialis Obstetri Ginekologi,
yang sebelumnya telah menyamakan persepsi mengenai penilaian
standarisasi sampel. Analisis statistik menggunakan uji Fisher.
Hasil: Terdapat hubungan bermakna ekspresi telomerase sedang dan
negatif di inti dan sitoplasma dengan tumor jinak ovarium dan tumor
ovarium borderline, dengan odd ratio ekspresi telomerase sedang di
sitoplasma dan inti sebesar 19,3 ( IK 95%: 1,4 - 943) dan 26 (IK 95%:
2,3 - 1211). Ini berarti bahwa risiko terjadinya tumor ovarium border-
line pada ekspresi telomerase sedang di sitoplasma adalah 3,19 kali
dibandingkan ekspresi negatif, sedangkan di inti 26 kali lipat. Tidak
terdapat hubungan bermakna menopause dan usia dengan ekspresi
telomerase di inti dan sitoplasma.
Kesimpulan: Terdapat perbedaan bermakna ekspresi telomerase
kekuatan sedang di inti dan sitoplasma tumor jinak dan tumor
ovarium borderline.
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tion degree and the good prognosis.3 Pathogenesis
of borderline ovarian tumors remain unclear, the
clinical management is still controversial, espe-
cially for borderline ovarian tumors serous type,
which is a type of borderline ovarian tumors
mostly found.4
Ovarian cancer pathophysiology has not been
clear until now. One of the interesting things to ex-
amine is the role of telomerase in cell aging proc-
ess. Telomerase is a complex ribonucleoprotein
that adds base sequences at the 3 ’end of DNA
telomere. Telomere length is maintained by telo-
merase, which is a specific DNA polymerase.
Telomere in humans will be shortened progres-
sively along with cell division.5 Malignant cells have
high telomerase activity so referred as the survival
cells that will continue to survive.6,7 Telomerase ac-
tivity has been widely found in various kinds of
malignant ovarian tumors, and rarely found in be-
nign tumors or normal ovarian tissue.8 Telomerase
can be used as a prognostic indicator in several
types of cancer, in which telomerase activity in-
creased in line with tumor progression.9-11
Borderline ovarian tumors are tumors that are
interesting to study because it is not benign nor
malignant tumors. Telomerase activities in border-
line ovarian tumors vary in several studies. Several
studies had shown that telomerase activity ranged
between 60-100%, while other studies showed the
number to be 17-20%.7 Telomerase is active in
most tumor cells, but not in normal somatic cells,
and can prevent progressive telomere shortening
in the presence of cell division, causing tumor cells
grew faster than normal cells.9,10 Stabilization of
telomeres by telomerase can lead to unlimited cell
proliferation.12 In malignant tumors such as leuke-
mia, breast cancer, and meningioma, telomerase
activity associated with a poor prognosis. Up until
now there is no sufficient data to determine the
role of telomerase as a factor in ovarian cancer
prognosis.7 So we need a study to determine the
effect of highly telomerase activity in malignant
ovarian in relation to carcinogenesis of ovarian
cancer so that it can be used as the basis for sub-
sequent studies as a prognostic approach and
treatment of malignancy, especially in malignant
epithelial ovarian tumors. The purpose of this
study is to determine the expression of telomerase
in benign ovarian tumors, borderline ovarian tu-
mors and assess the comparative telomerase ex-
pression in borderline and benign ovarian tumors.
METHOD
This study was a case-control study. Research was
conducted at the Department of Obstetrics and Gy-
necology and Department of Pathology Anatomy
Faculty of Medicine/RSUPNCM, started in July until
November 2011.
Research sample was all paraffin blocks at the
Department of Pathology Anatomy Faculty of
Medicine/RSUPNCM of benign ovarian tumors and
borderline ovarian tumors patients treated in on-
cology ward of Department of Obstetrics and Gy-
necology Faculty of Medicine/RSUPNCM from
January 2006 to December 2011 and meet the in-
clusion criteria were specimens collected from
January 2006, from patients who did not suffer
from malignancies in other organs, and had a com-
plete medical records. The exclusion criteria were
the paraffin blocks of non-epithelial ovarian tu-
mors. The sampling will be done in simple random
sampling, where all the paraffin blocks of ovarian
tumors that meet the criteria will be numbered,
and some of them will be selected with the help of
random tables. Based on the sample calculation, we
obtained 13 samples of benign ovarian tumors and
13 borderline ovarian tumors.
The paraffin blocks of borderline ovarian tumors
and benign ovarian tumors were stained immuno-
histochemically. The intensity of staining was
evaluated subjectively using a scale ranging from
0 = no stain, 1 = weak staining, 2 = moderate stain-
ing, 3 = strong staining.36 In every staining, we in-
cluded a negative control by using the same ova-
rian tissue and each one time staining process, we
made as much as 13 sample for case-control group
with a positive control of endometrial cancer.
Telomerase expression in cytoplasm and nu-
cleus, were assessed by immunohistochemical
staining, using Burstman score. Assessment cate-
gories: number of positive cells: 0% = 0; < 10% =
1; 10-50% = 2; 51-80% = 3; and > 80% = 4. The
intensity of color: Weak = 1+; Moderate = 2+;
Strong = 3 +. Then multiplied and the result: nega-
tive = score 0; weak = score 1; moderate = score
2-6; strong = score 8-12.
The research data were recorded on the form of
research that had been tested. After going through
the process of editing and coding, data that has
been a net will be processed and compiled in dis-
tribution and cross-table tabular form according to
the purpose of research, using SPSS software ver-
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sion 17.0. The relationship between telomerase ex-
pression in borderline ovarian tumors and benign
ovarian tumors was assessed by chi square tests
or Fisher. The predictive value is considered sig-
nificant if p value < 0.05. This research had re-
ceived approval from the Faculty of Medicine Re-
search Ethics Committee.
RESULT
Data were obtained from immunohistochemical
examination of 26 paraffin block samples which
were still in a good condition. Samples were de-
rived from borderline ovarian tumors and benign
ovarian tumor patients treated at the oncology
ward of Department of Obstetrics and Gynecology
Faculty of Medicine/RSUPNCM Jakarta in January
2006 to December 2011. Immunohistochemical
examination of samples from both groups was
done by assessing the number of positive cells and
intensity in the nucleus and cytoplasm. Assessment
of telomerase expression was carried out using
Burstman scores, then the samples divided into
groups of strong, moderate, weak and negative.
The data obtained from the examination was then
processed using SPSS version 17.0 for windows.
The number of cases, of patients with borderline
ovarian tumors were 13 people, and control group
consisted of 13 people. Fifteen patients (57.7%)
aged over 30 years and 11 (42.3%) aged less than
30 years. The average age of patients with border-
line ovarian tumors was older, and statistically sig-
nificant (41 ± 15 year) compared to benign ovarian
tumor group (25 ± 10 year).
To determine differences in age and parity
groups of benign ovarian tumors and borderline
ovarian tumors, we used the Mann Whitney test
because the data is abnormally distributed. To find
out the difference proportion of women who had
experienced menopause and have not experienced
menopause, and the proportion of histologic types
in each group, we used Chi square or Fisher test.
There are significant differences in the number of
patients who had experienced menopause in the
group of benign ovarian tumors and borderline
ovarian tumors. Histopathology types of benign
ovarian tumors are mostly mucinous, but there
were no significant differences in the proportion of
serous and mucinous types in both groups.
Table 1. The baseline characteristic of patients
Patients
characteristic
Benign ovarian
tumors
Borderline
ovarian tumors
p
value
Age 25 ± 10 41 ± 15 0.008*
Parity 1 (0-3) 2 (0-8) 0.047*
Menopausal status
Non-menopause
Menopause
13 (50%)
0 (0%)
9 (34.6%)
4 (15.4%)
0.048**
Histologic types
Serous
Mucinous
 1 (3.8%)
12 (46%)
 5 (19.23%)
8 (30.8%)
0.08**
Stage
IA
IIIC
9 (69.2%)
4 (30.8%)
*Mann Whitney test
**Fisher test
We classified the samples into 4 different
groups, namely the negative cases (score 0), weak
expression (score 1), moderate expression (score
2-6), and strong expression (8-12). To determine
the relationship between borderline and benign
ovarian tumors and the telomerase expression in
nucleus and cytoplasm, we used Fisher’s test. The
results of Fisher’s test can be seen in the following
table.
Table 2. Bivariate analysis of weak and moderate telo
 merase expression in the cytoplasm for case
 and control groups
Telomerase
expression
Group
OR
(CI 95%) p*Borderline
ovarian tumors
Benign ovarian
tumors
Weak 1 2 3.5 (0.03-313) 0.42
Negative 1 7 Reff
Moderate 11 4 19.3 (1.4-943) 0.005
*The predictive value (p) obtained via two-way Fisher’s test
There is a significant relationship between nega-
tive and moderate telomerase expression in the
nucleus and cytoplasm of benign ovarian tumors
and borderline ovarian tumors, with an odds ratio
of moderate telomerase expression in the cyto-
plasm and nucleus as much as 19.3 (95% CI: 1.4 -
943) and 26 (95% CI: 2.3 - 1211). This means that
the risk of borderline ovarian tumors in the mod-
erate telomerase expression in the cytoplasm was
3.19 times compared to the negative expression,
whereas in the nucleus 26-fold. In contrast, there
was no significant difference in weak and negative
telomerase expression for benign ovarian tumors
and borderline ovarian tumors in the nucleus and
cytoplasm.
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Table 3. Bivariate analysis of weak and moderate telo-
 merase expression in the nucleus for case
 and control groups
Telomerase
expression
Group
OR
(CI 95%) p*Borderline
ovarian tumors
Benign ovarian
tumors
Weak 0 1 1.3 (0.02-30)** 1.0
Negative 4 12 Reff
Moderate 9 0 26 (2.3-1211)** 0.00
*The predictive value (p) obtained via two-way Fisher’s test
**Odds ratio is obtained by adding 1 to each cell, because there is a cell
 whose value is 0
To determine the relationship between the age
and telomerase expression in the nucleus or cyto-
plasm, we used the two-way Fisher’s test. The age
was classified into two groups, which were = 30
years old and < 30 years old. According to two-way
Fisher’s test, there is no significant relationship be-
tween age and telomerase expression in the nu-
cleus (p value = 0.1) nor the cytoplasm (p value =
0.2). Based on two-way Fisher’s test, we found no
significant relationship between menopausal status
and telomerase expression in the nucleus (p value
= 0.11) nor the cytoplasm (p value = 0.3). Telom-
erase expression in both the nucleus and cyto-
plasm in borderline ovarian tumors with serous
and mucinous types showed no significant differ-
ences (p value > 0.05). We analysed the relation-
ship between borderline ovarian tumor stage and
telomerase expression, and there is no significant
relationship between borderline ovarian tumor
stage and telomerase expression in the nucleus and
cytoplasm (p value > 0.05).
These following pictures are immunohisto-
chemical examinations of benign ovarian tumors
and borderline ovarian tumors.
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DISCUSSION
Borderline ovarian tumors accounts for 10-15% of
all epithelial ovarian tumors, more than 96% of its
histopathology type is mucinosum or serous. Other
types can be either endometrioid, clear cell or tran-
sitional cell tumors (Brenner). This study included
26 samples that are divided into two groups: case
group, which is a sample derived from borderline
ovarian tumors, a total of 13 samples, and the con-
trol group, which is originated from benign ovarian
tumors, a total of 13 samples. In the case group,
mean age of patients is higher (41 ± 15) than the
control group (25 ± 10) and statistically significant.
These results are consistent with research con-
ducted by Ayhan et al, in which the average age of
patients with borderline ovarian tumors was 41.77
± 13.8844.13 The same conclusion is also reported
by Berek, et al in 2007, who stated that borderline
ovarian tumors mostly occur at age 30 - 50 years,
while ovarian cancer generally occurs between the
ages of 50 - 70 years. Incidence of borderline ovar-
ian tumors or invasive ovarian tumor is 1 in 10
patients aged 40 years, and after age 40 years, the
incidence will increase to 1 in 3 women.10 It is be-
cause borderline ovarian tumor is neoplasm with
changes in cell proliferation greater than that seen
in benign ovarian tumors of the same type, but
showed no destruction or invasion of the ovarium
stromal.1 Levi, et al, 1999, stated that the border-
line ovarian tumors are epithelial ovarian tumor
whose invasion is limited, have a good prognosis
and occurs at the younger age.14
In this study, multiparity patients are more
widely available in groups of borderline ovarian tu-
mors compared to benign ovarian tumors, and
these differences were statistically significant (p =
0.047). This is contrasting to the research con-
ducted by Riman et al, who reported that increas-
ing parity reduces the risk of borderline ovarian
tumor incidence.15 Parity is the most important
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nongenetic factor. Nagell and his colleagues ana-
lyzed the 12 case-control study in the United States
and they reported a significantly decreased risk of
ovarian cancer incidence in the presence of term
pregnancies (OR = 0.47). The risk of ovarian cancer
decreased progressively with increasing number of
pregnancy.16 Ovarian cancer is associated with low
parity and infertility. The relationship between
parity and infertility on the risk of developing ovar-
ian cancer have led to the hypothesis that suppres-
sion of ovulation is probably an important factor.
Theoretically, the epithelium surface having a de-
cay and repair process repeatedly. This process is
thought to cause a high probability of occurrence
of mutations that can lead to oncogenic pheno-
type.10
The most commonly found histologic type of
borderline ovarian tumors was serous, meanwhile
the most commonly found histologic type of benign
ovarian tumors was mucinous type. However, the
difference was not statistically significant (p =
0.08). In some literature it is said that the most
common histopathologic type of borderline ovar-
ian tumors is serous. Research conducted by Ayhan
A, 2005, reported that the most commonly found
histopathologic type of borderline ovarian tumors
was serous (54%) followed by mucinous (39%)
and other types of 7%.13 Another study conducted
by Levi, et al, stated the same thing, with the num-
ber of borderline ovarian tumors was 58% serous,
41% mucinosum, and 1% of other types.14 Most
borderline ovarian tumors found is on stage IA
which accounts for 61.5%. In accordance with re-
search conducted by Andrijono, most borderline
ovarian tumors were diagnosed at stage I (50% -
90%), so the conservative surgery can be easily
performed.17
All patients diagnosed as having benign ovarian
tumors in this study have not been through meno-
pause, while in the group of borderline ovarian tu-
mors, there were four (15.4%) patients who had
experienced menopause. This is related to age of
onset of borderline ovarian tumors, which gener-
ally occurs in older age compared to benign ovar-
ian tumors. In this study the average age of pa-
tients in the benign ovarian tumors were younger,
and statistically significant.
Measurement of telomerase activity varies
widely, as a diagnostic and prognostic modalities
for some cancers. In this study, we evaluated the
expression of telomerase in 26 patients with be-
nign ovarian tumors and borderline ovarian tu-
mors. Expression of telomerase is not only found
in the nucleus, but also in the cytoplasm. hTERT is
the catalytic subunit of telomerase which is over-
expressed in most tumor cells, and is required to
maintain telomere length. Therefore, hTERT usu-
ally work in the nucleus cell. But hTERT is also
found in the mitochondria, to maintain catalytic ac-
tivity. Some studies suggest that hTERT transloca-
tion to mitochondria is in oxidative stress condi-
tions. Phosphorylation at Tyr-707 in the presence
of oxidative stress, causing translocation of hTERT
from the nucleus to the cytoplasm and reduced an-
tiapoptosis activity. Phosphorylation by AKT path-
way led to hTERT location which is in the core.
Transfer of hTERT from the nucleus to the cyto-
plasm is highly dependent on the cell cycle, phos-
phorylation status, transformation and DNA de-
struction.18
The only benign ovarian tumors that showed
weak expression in the nucleus is the mucinosum
type. There are five patients with mucinosum be-
nign tumors that showed moderate expression in
the cytoplasm. In the serous type benign tumor,
telomerase expression was not found either in the
nucleus nor the cytoplasm. However, the distribu-
tion of histopathology in benign tumors is uneven,
where there is only one serous ovarian tumor.
Burstman, 2005 conducted a study to determine
the use of immunohistochemical expression of
telomerase in benign tumors, borderline and ma-
lignant ovarian tumors. In this study, he reported
that there is no telomerase expression in both the
nucleus nor cytoplasm in benign ovarian tumors.
Whereas in borderline ovarian tumors, 7 of 10
cases (70%) showed strong expression of hTERT
in the nucleus.9 Another study conducted by Kyo
et al 1998, stated that telomerase activity most
commonly found in malignant ovarian tumors, and
very rarely found in benign tumors ovarium.19
Telomerase activity is positive in some benign
ovarian tumors. Some of the regenerated tissue
and proliferated cells showed that telomerase ac-
tivity is lower.18
Most telomerase expression is obtained in
groups of borderline ovarian tumors, both in the
nucleus and the cytoplasm. In borderline ovarian
tumors there were 4 samples that showed no
telomerase activity in the nucleus, and one sample
in the cytoplasm. Research conducted by Park et
al, showed one borderline ovarian tumor samples
and one sample of malignant ovarian tumors which
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showed no telomerase activity or hTERT gene ex-
pression. This likely occurs because the tumor has
not yet demonstrated the telomerase regulation ac-
tivity. However, the interesting thing is the exist-
ence of alternative mechanisms of telomere elon-
gation in immortal cells and some tumors, even
though there is no telomerase activity.20 We ana-
lyzed the data with chi-square with a 2x2 table and
obtained statistically significant differences be-
tween the moderate telomerase expression in the
cytoplasm. Research conducted by Kyo et al,
Burtsman et al, on immunohistochemical examina-
tion to determine the expression of hTERT in ovar-
ian tumors, reported that hTERT expression is not
only happened in the nucleus, but also in the cyto-
plasm. This statement is supported by Western
blot examination of the nucleus and cytoplasm ex-
tracts, where the nucleus and the cytoplasm
showed a significant expression of hTERT. Biologi-
cal function of hTERT cytoplasm remains specula-
tive, the possibility of hTERT is located in the cy-
toplasm is prior to translocation to the nucleus. It
is said that cytoplasmic hTERT is not phosphory-
lated and inactive and that the phosphorylation of
hTERT associated with translocation from the cy-
toplasm to the nucleus.21
Chi-square analysis was used to determine the
relationship between histologic type of tumor and
telomerase expression in the nucleus, and signifi-
cant results obtained on the relationship between
the moderate expression in the nucleus (p = 0.000).
However, greater odds ratio is obtained for expres-
sion in the nucleus (26) compared to expression in
the cytoplasm (19.3). Another study conducted by
Sun, et al, to evaluate telomerase activity and
hTERT expression in clinical pathology of ovarian
tumors concluded that from 10 borderline ovarian
tumors cases, telomerase activity assay is per-
formed by RT-PCR analysis of hTERT mRNA and 2
of 10 (20.0%) who showed telomerase activity.
Telomerase activity in borderline ovarian tumors
increased significantly compared to benign ovarian
tumors and ovarian normal.22
Telomerase is believed to be critical for the con-
tinued growth of cancer cells, in the absence of this
enzyme, telomere length in cells that are dividing
will be too short for the next chromosome replica-
tion. This idea is supported by the presence of
telomerase activity during progression of cancer
cells that led to the interesting idea that the inter-
ference function of telomerase can be an efficient
approach to cancer therapy. The truth that telom-
erase is expressed in most, though not all, ovarian
cancer, has potential applications for the detection
of these tumors in clinical specimens. Malignant
ovarian tumors usually spread to pelvic and ab-
dominal cavity, unlike most other malignant tu-
mors that rarely metastasize outside the cavity. Cy-
tological examination of ascites fluid or pelvic or
abdominal cavity fluid can be used to determine
the activity of telomerase as a marker of tumor-
specific, to complete the conventional approach for
monitoring disease progression and theraupetic ef-
fects.23
In this study, we found no significant relation-
ship between age and the degree of telomerase ex-
pression in the nucleus and cytoplasm. Similar re-
sults were reported by Kyo, 1999 with a different
inspection techniques ie no significant relationship
between hTERT expression and age also clinical
stage.24 Research conducted by Murakami, et al,
1997, which analyzes the length of telomeres in
normal ovaries of women with varying ages to de-
termine whether telomere shortening occurs in
line with increasing age. It was found that, TRFs
size range between 8-13 kbp and the length does
not vary with increasing age.25 This is because
there are other factors that affect the expression of
telomerase. In a study conducted by Widschwend-
ter et al, 2004 they found that hTERT methylation
found more frequently in older patients. hTERT
methylation never been found in ovarian cancer or
in normal ovary patients aged less than 40 or 60
years. In that study, they also reported an in-
creased frequency of experiencing hTERT methy-
lation along with increasing age, while the expres-
sion of hTERT mRNA is not affected by age.26
We also analyze the relationship between meno-
pause and telomerase expression, and found no
statistically significant association between meno-
pausal status with telomerase expression in the nu-
cleus nor the cytoplasm. In contrast to research
Burstman, 2005, that found increased expression
of telomerase in the group of women who had ex-
perienced menopause compared to women who
have not experienced menopause.9 Murakami,
1997 conducted a study of normal ovarian pre-
menopausal women, and get a weak telomerase ex-
pression in the cortex 3 of 4 (75%) premenopausal
women (detected only 6 μg protein extracts), but
those expression is not found in the medulla.
Telomerase activity was not found in normal ova-
ries of women who already menopause.25 Wid-
schwendter et al, 2004, reported that telomerase
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is expressed by a very weak strength in normal
ovaries. hTERT expression of ovarian cancer and
normal ovarian significantly different. However, no
statistically significant relationship found between
age and telomerase expression.26
Statistical test is performed to determine the re-
lationship between tumor stage and telomerase ex-
pression only for borderline ovarian tumors. Based
on Fisher’s statistical test, there was no statistically
significant relationship between tumor stage and
telomerase expression. This is consistent with re-
search conducted Burstman, 2005, which reported
no significant relationship exists between the stage
and telomerase expression. In Burstman studies,
they also used immunohistochemical staining, but
the samples derived from borderline ovarian tu-
mors and malignant ovarian tumors. Research con-
ducted by Sun, et al reported an average increase
of telomerase activity happened in advanced ovar-
ian carcinoma (FIGO stage III / IV) than early-stage
(FIGO stage I / II), but the level of telomerase ac-
tivity between the two sub-groups did not differ
significantly.13 The same is expressed by Wid-
schwendter et al, 2004, who found no significant
relationship between tumor stage, histopathology,
and telomerase expression degree.26 Different re-
sults were reported by Satoru Kyo, et al who con-
ducted a study to determine the relationship of
telomerase activity and clinical pathology of ovar-
ian tumors . Average telomerase activity in tumor
stage Ia+, Ib, Ic, II, III, and stage IV was 30 ± 10,
38 ± 9, 47 ± 23, 54 ± 17 and 11 ± 12 units. Telom-
erase activity in stage IV was significantly higher
than the stage of Ia+, Ib, Ic, and stage II. This sug-
gests that telomerase activity increases with ovar-
ian cancer progression.20
Although some literature said that hTERT ex-
pression is regulated differently in various tissues,
it is strongly influenced by several control mecha-
nisms, such as a tumor suppressor, inhibition of the
cell cycle, hormone receptors and protein virus.20
All serous papilyferum types of borderline ovarian
tumors express telomerase with moderate strength
in the nucleus and cytoplasm, however there is no
statistically significant relationship between the
histologic types of ovarian borderline tumors with
telomerase expression. Research conducted by
Tantbirojn et al, reported that the serous type of
borderline ovarian tumors highest level of hTERT
expression. Overall there were no significant dif-
ferences between immunoreactivity of borderline
ovarian tumors and their histology type. hTERT
immunoreactivity in that study were not found in
benign tumors ovarium.27 Sehdev et al, 2003 re-
ported that serosum papiliferum type of borderline
ovarian tumor tend to bilateral (59-82%), ovarian
surface involvement (50-65%), found in an ad-
vanced stage (43-84%), microinvasive focus and
invasive implants (16-91%), so that the recurrence
incidence is high.28
This study has several drawbacks, including the
limited number of cases. Despite the limitations,
this study can be counted as a preliminary study,
and it is necessary to conduct further studies with
more samples.
CONCLUSION
Benign ovarian tumors mostly express telomerase
with the moderate strength in the cytoplasm. Bor-
derline ovarian tumors express telomerase with
the moderate strength in the nucleus. There is a
significant relationship between borderline ovar-
ian tumors and benign ovarian tumors with mod-
erate and negative telomerase expression in the
nucleus and the cytoplasm.
Further research with larger sample size is
needed to determine the role of telomerase expres-
sion as a diagnostic and prognostic modalities for
ovarian tumors and comparison of quantitative
and semiquantitative examination to assess the ex-
pression of telomerase in each type of ovarian tu-
mors.
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